MeiraGTx Netherlands B.V. is an Amsterdam based biopharmaceutical company developing local gene therapy for different indications. The company specializes in the development of viral gene therapy vectors, in particular adeno-associated virus (AAV) based therapeutics. Our goal is to develop potentially curative treatments for patients living with serious diseases. Several product candidates are in the discovery and development phase. Meira GTx Netherlands B.V. is a wholly-owned subsidiary of MeiraGTx Holdings plc. With sites in New York, London, Shannon and Amsterdam, our global footprint provides us the opportunity to partner with leading institutions around the world, allowing us to deepen our understanding of diseases and their progression.